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Abstract
Background: Melanoma is one of the most invasive and aggressive types of cancer with a very poor prognosis.
Surgery remains the most efficient treatment prior melanoma invasion and metastasis formation. However, therapy
becomes a challenge once the cancer cells colonized other tissues. At present, there are two main classes of
therapies acting with a certain efficiency on metastatic melanoma: immune check point inhibitors (anti-PD1/PDL1)
and targeted therapy such as Vemurafenib. Unfortunately, these therapies are not fully responsive, induce resistance
and/or generate unwanted side effects. In this respect, it is important to continue to discover new cancer
therapeutics. Here, we show that daphnane diterpenes type of compounds can prevent melanoma metastasis by
inhibiting metastasis-associated matrix metalloproteinases expression without cytotoxicity.
Methods: Evaluation of the anti-metastasis effect of daphnane diterpenes-rich Thymelaea hirsuta extract (TH) and its
bioactive component gnidilatidin was carried out in vitro using B16 murine melanoma cells and in vivo using male
C57BL/6 J mice. Global gene expression in B16 cells was done using DNA microarray, validated using real-time PCR,
to further understand the effect of daphnane diterpenes, specifically daphnane diterpenoid gnidilatidin.
Results: Oral administration of daphnane diterpenes-rich Thymelaea hirsuta extract (TH) suppressed MMP2 and
MMP9 expression, decreasing lung tumor in mice injected with B16 murine melanoma cells. Validation of these
observations in vitro showed reduced B16 cells migration, adhesion, and invasion. Results of microarray analysis of
B16 cells treated with daphnane diterpenoid gnidilatidin from TH revealed an upregulation of tumor suppressor
Egr1 while inhibiting metastasis-associated genes Id2 and Sytl2 expression. A downregulation of the melanoma
oncogene microphthalmia-associated transcription factor (Mitf) was observed, and most likely caused by the
inhibition of Id2, a gene that regulated HLH transcription factors such as MITF and also reported to promote tumor
cell migration and invasion.
Conclusions: Daphnane diterpenes have inhibitory effect on the metastatic potential of B16 melanoma cells, and
the results of this study provided evidence for their potential for use in the prevention and inhibition of melanoma
metastasis.
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Background
Melanoma is the most aggressive type of cancer, and
among solid tumors, its incidence is rising faster, with a
global incidence of about 48,000 and 160,000 deaths
annually [1]. Surgery remains an attractive option for
treatment of melanoma coupled with chemotherapy that
requires long-term treatment that often do not achieve
the expected response nor provide evidence for their effi-
cacy [2]. Moreover, therapy becomes a challenge once the
cancer cells metastasize and colonize other tissues. Des-
pite significant leaps in terms of diagnosis, surgery, and
patient care, highly invasive and metastatic melanoma,
that has disseminated to distant sites and the visceral or-
gans and the brain, is almost always incurable, decreasing
the medial survival time to only 6–9 months [2–4], mak-
ing it one of the most therapeutically challenging diseases
[5]. Curative treatments for patients with metastatic
melanoma remain elusive while available treatments have
severe adverse effects. Ipilimumab, for example, is associ-
ated with immune-mediated diarrhea and colitis; dacarba-
zine with respiratory toxicity and dyspnea [6]. Cell-matrix
adhesion molecules, integrins, and their interaction with
extracellular matrix promotes cell movement or metasta-
sis [7] while matrix metalloproteinases (MMPs) degrade
the matrix proteins and regulate cell activities with rele-
vance for cancer, playing a crucial role in the cell migra-
tion and metastasis formation [8]. Among the MMPs,
MMP9 form a complex with CD44, a cell surface mol-
ecule that mediates cell migration and resistance to
anti-cancer drugs [9, 10]. So far, studies on the use of
small molecule inhibitors for MMPs (for a variety of
tumor types) that have reached clinical trials, have been
unsuccessful [11]. Naturally occurring daphnane-type di-
terpene orthoesters have antileukemia, anticancer, toxic, or
neurotrophic effects [12] and therefore provide an alterna-
tive source of cancer therapeutics. We have previously re-
ported on the melanogenesis inhibitory effects of daphnane
diterpenes-rich Thymealea hirsuta [13] and two of its
daphnane diterpenoids components, hirsein A and hirsein
B [14]. Hirseins A and B downregulated microphthalmia-
associated transcription factor (MITF) leading to melano-
genesis inhibition. In melanoma cells, reduction of the
MITF activity has been observed to sensitize the cancer
cells to chemotherapeutic agents [15]. MITF also controls
melanoma proliferation and invasiveness via regulation of
Dia1 [16]. Daphnane diterpenoid mezerein in combination
with recombinant human fibroblast interferon (IFN-beta)
has antiproliferative properties in human melanoma cells
and functions as a negative regulator of melanoma progres-
sion [17]. T. hirsuta extract contains at least six daphnane
diterpenes: hirseins A and B [18], gnidicin, gniditrin, gen-
kwadaphnin, and gnidilatidin [19]. Here, we investigated
the effects of daphnane diterpenes-rich T. hirsuta extract
on the metastatic potential of B16F10 cells in vivo, using
syngeneic male C57BL/6 J mice, and in vitro using the
B16F10 melanoma cells known to be malignant melanoma
cells that are stable in their metastatic potential. Since TH
contains not just daphnane diterpenes, the possible mo-
lecular mechanism underlying the effect of TH was deter-
mined in vitro using one of TH components - daphnane
diterpene gnidilatidin.
Methods
Animals/declarations for the animal research
Six (per treatment group) seven (7)-weeks-old male
C57BL/6 J mice (Charles River Laboratories Japan, Inc.)
were housed individually in polycarbonate cage lined with
paper bedding (Palsoft Oriental Yeast Co., Ltd., Tokyo,
Japan) with stainless wire cover and maintained under
standard conditions with free access to food and water,
and housed in a 12-h light/dark cycle room. The animals
were sacrificed using the cervical spine dislocation
method. All the experiments complied with the
guidelines of the University of Tsukuba’s Regulation
of Animal Experiments and were approved by the
University of Tsukuba’s Committee on Animal Care
and Use (No. 16–046).
Cell culture
B16F10 murine melanoma cells (B16 cells) were obtained
from RIKEN, Tsukuba (Catalog No. RCB2630:B16F10) and
cultured in RPMI1640 (Gibco, Invitrogen GmbH,
Karlsruhe, Germany) supplemented with 10% fetal bovine
serum (FBS) and incubated at 37 °C in a humidified
atmosphere of 5% CO2. For mouse tail vein injection, 1 ×
106 cells/ml B16 cells were resuspended in saline solution,
which was then passed through a 79-μm-cell strainer (BD
Falcon, BD Biosciences, San Jose, CA, USA) before injec-
tion to remove aggregated cells.
Samples
Daphnane diterpenes were treated as ethanolic extract
of air-dried Thymelaea hirsuta leaves (10 g in 100 mL of
70% EtOH). T. hirsuta extract (TH) was passed through
a 0.22 μm filter (Millipore, Germany) and stored at −
80 °C °C until use. Ethanol in the TH samples for oral
administration was removed by evaporation (SCRUM
Inc., Tokyo, Japan) and dissolved in distilled water. Gni-
dilatidin (MW: 648.749 g/mol) was extracted from T.
hirsuta following a similar protocol for isolating hirsein
A and hirsein B, as previously reported [18] TH (100 g/l
70% EtOH) contains about 0.5 mg gnidilatidin. Prelimin-
ary screening assays using different concentrations of
gnidilatidin (data not shown) revealed that gnidilatidin
was effective but not cytotoxic at concentrations of 0.1
to 1.0 μM so for this study, gnidilatidin was used at
0.1 μM concentration in all the experiments.
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Tumorigenesis assays
C57BL/6 J mice (7 mice/group) were allowed to acclimatize
for a week before they were randomly divided into four
groups: Controls of “(−) B16F10” group injected with water
and given tap water and “(+)B16F10 group” injected with
B16F10 cells and given tap water; “DTIC/(+)B16F10 group”
injected with B16F10 cells and orally-administered with
70 mg/kg/day dacarbazine (DTIC) and is the positive con-
trol; the “TH/(+)B16F10 group” injected with B16F10 cells
and orally-administered with 50 mg/kg/day T. hirsuta ex-
tract. After acclimatization, mice lateral tail veins were
injected with B16F10 cells (2 × 105 tumor cells in 100 μl
PBS, 0.2 ml/mouse). The day after B16F10 injection, every
morning in the animal room, mice were orally adminis-
tered, to ensure that each animal receive the exact dosage
corresponding to each animal’s body weight, with DTIC or
TH everyday for 20 days. Food and water were given ad
libitum during the experimental period. The day after the
last oral administration, the mice were sacrificed using the
widely accepted method which is cervical spine dislocation
and the lungs were collected, washed, the number of lung
tumor colonies was counted, then frozen in liquid nitrogen
and stored at − 80 °C for protein and RNA extractions.
Mice body weight was recorded daily for 21 days.
Western blotting
Total protein was extracted from B16F10 cells or mice
lungs using Radio-Immunoprecipitation Assay (RIPA)
buffer following the manufacturer’s instructions. SDS-
PAGE (10%) was then carried out to resolve 10 μg of
extracted protein sample, which was then transferred to a
PVDF membrane (Merck Millipore, USA). Membranes
were incubated with primary antibodies against MMP2,
MMP9, and CD44 (obtained from Abcam, Cambridge,
UK), at 4 °C overnight, then washed and incubated with
secondary antibody, IRDye 800CW Donkey anti-rabbit
IgG (LI-COR, Inc., NE, USA), at room temperature for
30 min. The signal was detected using the OdysseyFc Im-
aging System (LI-COR, Inc., NE, USA). All protein quanti-
fications were normalized to β-actin expression level.
Cell proliferation assay
Cell proliferation was assessed using the 3-(4,5-
cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
or MTT (Dojindo, Japan) assay. B16F10 cells (3 × 104
cells/well) were seeded onto 96-well plates and cultured
as described above. After 24 h of incubation, the medium
was replaced with medium without or containing TH or
gnidilatidin at various concentrations. MTT (5 mg/ml)
was then added, the plates covered with aluminum foil,
and incubated further for 48 h. Sodium dodecyl sulphate
(SDS; 10%) was then added at 100 μl per well, and incu-
bated overnight at 37 °C to dissolve the formazan com-
pletely. Absorbances were obtained at 570 nm using a
microplate reader (Powerscan HT; Dainippon Pharmaceu-
ticals USA Corp., NJ, USA). Blanks containing medium
only was used to correct the absorbances.
Viable cell count
Viable cell count was performed using the ViaCount pro-
gram of Guava PCA (Millipore, Billerica, MA, USA).
B16F10 cells were seeded onto 10-mm dish (5 × 104 cells/
ml) and incubated for 24 h at 37 °C, after which, medium
was replaced with fresh medium without or containing TH
or gnilatidin. After further incubation for 48 h, cells were
collected and resuspended in 1 ml medium and stained
with DNA-binding Guava ViaCount reagent (Millipore)
and analyzed according to the manufacturer’s instructions.
Wound healing assay
B16F10 cells were seeded onto 6-well plates (5 × 105 cells/
well) until they reach 80% confluence when a scratch was
made on the cell monolayer using a sterile white pipette
tip, and washed with PBS (−) to remove the detached cells.
The growth medium was then replaced by fresh growth
medium without or with 1000 v/v TH or gnidilatidin. The
cells were photographed using Leica DFC290 HD camera
(Beckman Coulter, CA, USA) before scratching and at 0 h,
12 h, and 24 h following sample treatment. The images of
the cells before and after scratching in treated and un-
treated cells were then compared.
Cell adhesion assay
B16F10 cells were seeded onto 10-cm petri dishes (3 ×
105 cells/ml) and incubated for 24 h at 37 °C. After over-
night incubation, the medium was replaced with TH- or
or gnidilatidin-containing medium. After further incuba-
tion (24 h) cells were trypsinized and resuspended in
serum-free RPMI 1640 medium (2 × 105 cells/ml). The
cell suspensions (100 μl) were then seeded onto fibro-
nectin coated-plate (BD). After incubation for 1 h at 37 °
C, medium was removed and washed three times with
PBS (−) to remove the unattached cells, after which,
MTT assay was perfomed as described above.
Invasion assay
Invasion assay was performed using the 24-well Corning
BioCoat Matrigel Invasion Chambers containing Falcon
cell culture inserts (8 μh pore size PET membrane with
a thin layer of Matrigel basement membrane matrix
(Corning, Bedford, MA, USA), following the manufac-
turer’s instructions. B16F10 cells (5 × 105 cells/ml), in
serum-free media, were seeded onto the Matrigel-coated
chambers while 10% FBS was added to the lower cham-
ber as chemoattractant. After 24 h incubation, the lower
chamber was stained with DAPI (Vector Laboratories,
Inc., Burlingame, CA, USA), and the number of cells
that had invaded moved to the lower chamber was
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counted using Leica DMI-4000B fluorescence microscope.
Three fields in each sample were counted and the mean
values from three independent experiments were used.
DNA microarray analysis
DNA microarray was performed using Affymetrix (Santa
Clara, CA, USA) GeneChip Mouse Genome 430 2.0
Array following the manufacturer’s instructions. Total
RNA was extracted from B16F10 cells (3 × 105 cells/ml)
and the quality was assessed using Agilent 2100 bioana-
lyzer (Agilent Technologies). Biotin-labeled aRNA was
synthesized by in vitro transcription and the purified
aRNA (10 μg) was fragmented using the GeneAtlas 3’
IVT Express Kit, and was hybridized to the gene chip
for 16 h at 45 °C. The chips were washed and stained in
the GeneAtlas Fluidics Station 400 (Affymetrix) and the
resulting image scanned using the GeneAtlas Imaging
Station (Affymetrix). Identification of the differentially
expressed genes was performed using Affymetrix® Ex-
pression Console™ Software and Affymetrix® Transcrip-
tome Analysis Console (TAC) 2.0 Software (Affymetrix).
Quantitative real-time PCR
RNA (1 μg), extracted using Isogen reagent (Nippon Gene,
Tokyo, Japan), was reverse transcribed using the Super-
Script III reverse transcriptase kit (Invitrogen, Carlsbad,
CA, USA). Primers specific to Egr, Id2, Sytl2,Tyr,Trp1, Dct,
and Mitf were used for real-time PCR performed using
7500 Fast Real-time PCR system using TaqMan Universal
PCR mix and TaqMan probes (Applied Biosystems, Foster
City, CA, USA). All reactions were run in triplicate, and
data were analyzed using the 2 -Δ Δ CT values method.
Statistical analysis
Results were expressed as mean ± standard deviations
(SD), and the statistical evaluation performed using
Student’s t-test when two value sets were compared
(Control vs treated cells). ANOVA was performed to as-
sess the level of significance between groups’ number of
nodules and weight. A P value of ≤0.05 was considered
to be statistically significant.
Results
Daphnane diterpenes suppressed B16F10 cells lung
colonization
To investigate the effect of daphnane diterpenes on
tumor cell adhesion to mice lungs, the lung tumors that
formed from tail vein-injected B16F10 cells was counted
after 3 weeks of oral administration with 50 mg/kg of
daphnane diterpenes-rich T. hirsuta extract (TH) or
70 mg/kg/day dacarbazine (DTIC), the positive control.
Compared to untreated mice (+B16F10), a reduction in
tumor colonization (70%) was observed in “TH group”
and “DTIC group” (Fig. 1a and b). The number of nodules
Fig. 1 Effect of daphnane diterpenes on mice lung colonization by
B16F10 cells. a Photographs of lungs of mice injected without (−)B16F10
or with (+) B16F10, and treated with dacarbazine (DTIC) or 1/1000 v/v T.
hirsuta extract (TH). Arrows point to the lung nodules or tumors; b Plot
of the number of mice lungs nodules (tumor) in mice injected without
(−)B16F10 or with (+) B16F10, and treated with dacarbazine
(DTIC) or TH. **Statistically significant (P ≤ 0.01) difference
between treated cells and control
Fig. 2 Effect of daphnane diterpenes on the expression of MMP2
and CD44 in vivo. The expression of (a) CD44 (b) and metalloproteinases
MMP9 and MMP2 in mice injected without (−) B16F10 or with (+) B16F10,
and treated with dacarbazine (DTIC) or 1/1000 v/v T. hirsuta extract (TH).
Total proteins were then extracted and resolved by SDS-PAGE; the
resolved proteins were then blotted onto a PVDF membrane. CD44,
MMP2, and MMP9 were detected by immunoblotting with an anti-CD44,
anti-MMP2, or anti-MMP9, polyclonal antibodies. The signals were
visualized using LiCor Odyssey Infrared Imaging System after reaction with
goat anti-mouse IRDye 680LT, or goat anti-rabbit IRDye 800CW (LI-COR).
CD44, MMP2, and MMP9 levels were normalized to β-actin expression
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was significantly different among groups (P < 0.00001).
Tumors were observed in mice injected with B16 cells
while none in mice injected with just water (Control). No
significant difference in weight between mice groups was
observed (P = 0.1) (Additional file 1: Table S1).
Daphnane diterpenes decreased the metastasis-
associated proteins expression in mice lungs
CD44 and MMPs MMP2 and MMP9 are implicated in
the progression and metastasis of melanoma [10]. Deter-
mination of the effect of daphnane diterpenes on CD44
expression showed that mice injected with B16 cells had
higher CD44 level compared to the uninjected control
mice. Treatment with either TH or DTIC significantly
decreased CD44 expression (Fig. 2a,). In addition, B16
cells-injected mice had increased MMP2 and MMP9
levels (Fig. 2b) but after oral administration with TH or
DTIC, MMP2 and MMP9 levels were significantly low-
ered (Fig. 2b, Additional file 2: Figure S1).
Daphnane diterpenes have no effect on the proliferation
and viability of B16F10 cells
To establish if the observed decrease in MMPs and CD44
expression was not due to cytotoxicity of daphnane diter-
penes, B16 cells proliferation and viability were evaluated
using MTT assay and flow cytometry, respectively. Treat-
ment with 1/10,000, 1/1000, or 1/100 TH for 24 h, 48 h,
and 72 h had no significant change in the cell proliferation
of B16 cells after 24 h at all concentrations tested (Fig. 3a).
Extending the treatment time did not cause a significant
change either except for 1/100 v/v TH-treated cells.
Choosing 1000 v/v TH for the succeeding in vitro experi-
ments, flow cytometry evaluation of cell viability showed
that there was no significant difference between the
Fig. 3 In vitro evaluation of the effect of daphnane diterpenes on B16F10 cells metastasis. a Cell proliferation evaluated using the MTT assay;
b Viability of B16F10 cells treated with 1/000 v/v T. hirsuta extract (TH) evaluated using flow cytometry (Guava ViaCount assay); c Scratched cell
monolayer images for the wound healing assay results (cell migration assay); d Wound healing assay results; e Cell invasion results obtained
using the matrigel invasion assay; f Cell adhesion assay results evaluated by performing the MTT assay on B16 cells cultured in fibronectin-coated
96-well plates. Results represent the mean ± SD of triplicate samples. **Statistically significant (P ≤ 0.01) difference between treated cells
and control
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control and TH-treated cells (Fig. 3b). No significant dif-
ference was observed in the number of control and
TH-treated cells either (data not shown).
Daphnane diterpenes inhibited cell migration, invasion,
and cell adhesion
Results of wound healing analyses that monitored the cell
movement between the gaps of the scratch made showed
that compared to the control, TH decreased the gap cre-
ated over a confluent monolayer after 12 h and 24 h, but
not as fast as the control. In control (untreated cells) the
gap completely closed after 24 h (Fig. 3c and d). Measure-
ment of the ability of cells to degrade the basement mem-
brane revealed that treatment with daphnane diterpenes
(1/1000 v/v TH) inhibited the invasive ability of B16F10
cells by 12% (Fig. 3e). Evaluation of the B16F10 cells’
adhesion to the extracellular matrix (ECM) showed that
adhesion on ECM-coated plates was significantly reduced
(35%) by TH (Fig. 3f).
Effect of daphnane diterpenoid gnidilatidin on global
gene expression in B16F10 cells
To examine the mechanism of the effect of daphnane
diterpenes on melanoma, the global gene expression in
B16F10 cells treated with gnidilatidin, a daphnane
diterpene present in TH, was performed. Out of 39,000
transcripts, gnidilatidin upregulated 396 genes (> 2 ex-
pression ratio) significant for signal transduction (16%),
apoptosis (32%), cell adhesion (19%), and cell cycle
(33%), and downregulated 212 genes (< 0.5 expression ra-
tio). The top 10 genes upregulated by gnidilatidin are Egr1,
Zfp36, Fos, Junb, Nr4a1, Ier2, Sgk, Cyr61, Vasn, and Sertad
while the downregulated genes are Id2, Sytl2, Tbca,
Sorbs1, Zfp85-rs1, Esco2, Mtss, Zfp60, Psg28, and
Brca1 (Tables 1 and 2). The changes in the expres-
sion of Egr1, Vasn, Id2, and Sytl2, determined by
microarray to be significantly up- or downregulated,
were validated using quantitative real-time PCR. Results
show that indeed, treatment with gnidilatidin for 1 h
Table 1 List of top ten (10) upregulated genes in gnidilatidin-treated B16F10 murine melanoma cells as determined by DNA
microarray (Expression ratio of gnidilatidin vs Control)a
Gene Function Gnidilatidin (vs Control)
Egr1, early growth response 1 Required for differentiation and mitogenesis; a cancer suppressor gene;
activates expression of p53/TP53 and TGFB1, and thereby helps prevent
tumor formation.
113.24
Zfp36, zinc finger protein 36 Plays a role in the regulation of keratinocyte proliferation, differentiation
and apoptosis;
Plays a role as a tumor suppressor by inhibiting cell proliferation in breast
cancer cells.
30.69
Fos, FBJ osteosarcoma oncogene
Junb, Jun-B oncogene
FOS proteins have been implicated as regulators of cell proliferation,
differentiation, and transformation;
Transcription factor involved in regulating gene activity following the
primary growth factor response
20.57
Nr4a1, nuclear receptor subfamily 4,
group A, member 1
The encoded protein acts as a nuclear transcription factor. Translocation
of the protein from the nucleus to mitochondria induces apoptosis; May
inhibit NF-kappa-B transactivation of IL2. Participates in energy
homeostasis by sequestrating the kinase STK11 in the nucleus, thereby
attenuating cytoplasmic AMPK activation.
20.15
Ier2, immediate early response 2 DNA-binding protein that seems to act as a transcription factor; Involved
in the regulation of neuronal differentiation, acts upon JNK-signaling
pathway activation and plays a role in neurite outgrowth in hippocampal
cells.
16.86
Sgk1, serum/glucocorticoid
regulated kinase 1
Encodes a serine/threonine protein kinase that plays an important role in
cellular stress response. This kinase activates certain potassium, sodium,
and chloride channels, suggesting an involvement in the regulation of
processes such as cell survival, neuronal excitability, and renal sodium
excretion.
Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity.
13.23
Cyr61, cystein rich protein 61 Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion.
Appears to play a role in wound healing by up-regulating, in skin fibroblasts,
the expression of a number of genes involved in angiogenesis, inflammation
and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA,
PAI-1 and integrins alpha-3 and alpha-5. CYR61-mediated gene regulation is
dependent on heparin-binding.
12.13
Vasn, vasorin May act as an inhibitor of TGF-beta signaling. 11.03
Sertad1, SERTA domain
containing 1
Stimulates E2F1/TFDP1 transcriptional activity. Renders the activity of
cyclin D1/CDK4 resistant to the inhibitory effects of CDKN2A/p16INK4A.
10.33
aData based on the average of three samples
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increased the expression level of the Egr1 but decreased
Id2 and Sytl2 expression (Fig. 4a-c).
Gnidilatidin inhibited B16F10 cells migration and adhesion
Wound healing test on B16F10 cells treated with or
without gnidilatidin showed a significant decrease in the
ability of the Gnidilatidin-treated cells to “heal” the
scratch made on the confluent cell layer (Fig. 5a). The
same effect on wound healing was observed in
SK-MEL-28 cells (data not shown). Evaluation of the
B16F10 cells’ adhesion to the extracellular matrix (ECM)
showed that adhesion on ECM-coated plates was signifi-
cantly reduced (24%) by 24 h of gnidilatidin treatment (Fig.
5b). Determining the expression of extracellular membrane
proteins’ genes expression showed a significant decrease in
the expression of Mmp2, Mmp9, and Cd44 genes.
Gnidilatidin downregulated Mitf expression
MITF is the master regulator of melanocyte develop-
ment, function, and survival differentiation but at the
same time, promotes malignant behavior [20]. The effect
of gnidilatidin on the melanin content, the expression of
Mitf and to confirm the decrease in Mitf expression, the
expression of Mitf-regulated genes important for
melanogenesis such as tyrosinase (Tyr), tyrosinase-related
protein 1 (Trp1), and dopachrome tautomerase (Dct), as
well as the melanosome transport protein Rab27a was
then determined. Gnidilatidin downregulated Mitf
expression by 30% after 4 h of treatment, causing a de-
crease in the expression of the Tyr, Trp1, Dct, and Rab27a
(Fig. 5c-e). Moreover, gnidilatidin-decreased expression of
the melanogenic enzymes (to 85%) caused a dose-
dependent melanogenesis inhibition (50%) (Fig. 5d).
Table 2 List of top ten (10) downregulated genes in gnidilatidin-treated B16F10 murine melanoma cells as determined by DNA
microarray (Expression ratio of gnidilatidin vs Control)a
Gene Function Gnidilatidin (vs. Control)
Id2, inhibitor of DNA binding 2 Promotes tumor cell migration and invasion; The protein ID2
belongs to the inhibitor of DNA binding family, members of
which are transcriptional regulators that contain a helix-loophelix
(HLH) domain but not a basic domain.
0.16
Sytl2, synaptogaminlike 2 The SLP homology domain (SHD) of this protein has been
shown to specifically bind the GTPbound form of Ras-related
protein Rab-27A (RAB27A). This protein plays a role in
RAB27Adependent vesicle trafficking and controls melanosome
distribution in the cell periphery.
0.17
Tbca, tubulin cofactor a Tubulin-folding protein; involved in the early step of the tubulin
folding pathway.; The product of this gene is one of four proteins
(cofactors A, D, E, and C) involved in the pathway leading to
correctly folded beta-tubulin from folding intermediates.
0.19
Sorbs1, Sorbin and SH3 domaincontaining 1 This gene encodes a CBL-associated protein which functions in
the signaling and stimulation of insulin. Mutations in this gene
may be associated with human disorders of insulin resistance.
Required for insulin-stimulated glucose transport. Involved in
formation of actin stress fibers and focal adhesions (By similarity).
0.21
Zfp85-rs1, Zinc finger protein 85, related
sequence 1
Regulation of transcription, DNA-templated; nucleic acid binding;
metal ion binding; transcription corepressor activity
0.21
Esco2, Establishment Of Sister Chromatid
Cohesion NAcetyltransferase 2establishment
of cohesion 1 homolog 2
Acetyltransferase required for the establishment of sister chromatid
cohesion. Couples the processes of cohesion and DNA eplication to
ensure that only sister chromatids become paired together. In
contrast to the structural cohesins, the deposition and establishment
factors are required only during the S phase. Acetylates the cohesin
component SMC3.
0.22
Mtss1, metastasis suppressor 1 May be related to cancer progression or tumor metastasis in a
variety of organ sites, most likely through an interaction with the
actin cytoskeleton.
023
Zfp60, zinc finger protein 60 Negative regulator of cartilage differentiation 0.25
Psg28, pregnancyspecific glycoprotein 28 Relevant for cell adhesion and for positive regulation of
endocytosis, phagocytosis, and inflammatory response
0.26
Brca1, breast cancer 1 E3 ubiquitin-protein ligase that specifically mediates the formation
of Lys-6-linked polyubiquitin chains and plays a central role in DNA
repair by facilitating cellular responses to DNA damage. Required
for appropriate cell cycle arrests after ionizing irradiation in both
the Sphase and the G2 phase of the cell cycle. Involved in
transcriptional regulation of P21 in response to DNA damage.
0.27
aData based on the average of three samples
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Discussion
The use of natural products to prevent cancer has been
recognized to be effective. Tea catechins, for example,
have been demonstrated to have significant anti-cancer
and cancer metastasis preventive effects [21]. Moreover,
the use of natural products against melanoma and mel-
anoma metastasis, in particular, has been the focus of
several studies recently [22, 23]. In this study, we
demonstrated the potential of daphnane diterpenes as
therapeutics against melanoma metastasis. Based on the
in vivo tumorigenesis assay, treatment with daphnane
diterpenes-rich T. hirsuta extract (TH) decreased the
number of lung tumors in B16-injected mice (Fig. 1a-b)
without affecting mice weight and without cytotoxicity
(Additional file 1: Table S1, Fig. 3a) and comparable to
treatment with DTIC. The metastatic process requires
the following steps: attachment of the cells to the matrix
components, local degradation of the matrix by metallo-
proteinases, and migration of the cells to other parts of
the body. Daphnane diterpenes inhibited not just cell
migration, but also cell invasion and adhesion (Fig. 3c-f ).
The recruitment of cell adhesion molecule CD44 on
the surface of the cells is an important metastasis event.
CD44 regulates progression and metastasis of several
cancers such as breast cancer, prostate cancer, and mel-
anoma [10, 24–27] by interacting with extracellular
matrix that promotes cell motility [7] and has an affinity
for other ligands, including matrix metalloproteinases
(MMPs). MMPs are proteolytic enzymes and by degrad-
ing proteins, regulate the tumor environment, including
cell growth, differentiation, and angiogenesis. MMPs ex-
pression and activation is therefore increased in almost
all human cancers, including melanoma [28, 29]. Studies
have shown that CD44 functions as a docking molecule
for MMP9, suggesting a mechanism for CD44 cell mi-
gration [10]. Treatment with daphnane diterpenes-rich
TH suppressed both CD44 and MMPs (MMP2 and
MMP9) expression in vivo (Fig. 2a-b) preventing the for-
mation of a CD44/MMP9 complex on the cell surface is
indispensable for MMP9 activity [10].
Targeting MMPs for melanoma is also recognized as a
promising therapeutic strategy. Synthetic MMP inhibitors
have been looked to prevent metastasis. And while some
reached clinical trials, some were prematurely terminated
due to either lack of benefits or they cause unwanted
effects [28]. The metastasis inhibitory effects of daphnane
diterpenes without cytotoxicity (Fig. 3a and b) can be
attributed to the six daphnane diterpenoids contained in
TH [18, 19]. Further evaluation of the effect of daphnane
diterpenes on B16F10 cells using TH daphnane diterpen-
oid gnidilatidin revealed the mechanism involved in its
effect on metastasis. Gnidilatidin has a fatty acid-containing
structure and is an analogue of the anticancer compound
mezerein. Gnidilatidin (0.1 μM) has inhibitory effect on
metastasis-associated genes and was not cytotoxic at up to
1.6 μM. Highly upregulated gene, immediate early gene
(Egr1) (Table 1), encodes a nuclear, zinc finger protein and
its transcription directly regulates multiple tumor
a
b
c
Fig. 4 Quantitative real-time PCR of cancer metastasis-associated
genes expression in 0.1 μM gnidilatidin-treated B16F10 melanoma
cell lines. Relative gene expression levels of (a) Early growth
response 1 (Egr1), (b) Inhibitor of DNA binding (Id2), and (c)
Synaptogamin-like 2 (Sytl2) genes. Results represent the mean ± SD
of triplicate samples. **Statistically significant (P ≤ 0.01) difference
between treated cells and control
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suppressors such as TGFbeta, PTEN, p53, and fibronectin,
as well as the Sgk1 gene that phosphorylates BRAF and
MAP3K3 and inhibit their activities [30]. Furthermore, in-
duction of Egr1 expression is associated with a decreased
metastatic and invasive ability of human hepatocarcinoma
cells [31]. Downregulated gene (Table 2) Id2 is relevant in
the inhibition of helix-loop-helix transcription factors such
as MITF [32] while Sytl2 binds the GTP-bound form of
Ras-related protein Rab27a [33]. Id proteins (e.g. Id2) have
been reported to interact with MITF and inhibit its activity
[32]. In vitro analysis of the effect of daphnane diter-
pene gnidilatidin on B16F10 cell migration and adhe-
sion showed that it appeared to have slowed down
the healing of the gap in scratched cell monolayer in
the wound healing assay (Fig. 5a) and decreased cell
adhesion (Fig. 5b) and this can be attributed to the
downregulation of the Mmp2, Mmp9, and Cd44 gene
expression (Fig. 5c).
Fig. 5 Effect of gnidilatidin (0.1 μM) on wound healing, cell adhesion, and Mitf expression in B16F10 melanoma cell lines. a Scratched cell
monolayer images for the wound healing assay results (wound healing assay results; b Cell adhesion assay results evaluated by performing the
MTT assay on B16 cells cultured in fibronectin-coated 96-well plates; c Relative gene expression of Mmp2, Mmp9, and Cd44 genes; d Relative
gene expression of Mitf; e Relative gene expression of tyrosinase (Tyr), c tyrosinase-related protein 1 (Trp1), dopachrome tautomerase (Dct), and (f)
Ras-related protein (Rab27a), determined using TaqMan real-time quantitative PCR; g Melanin content of B16 cells. Results represent the mean ±
SD of triplicate samples. *Statistically significant (P≤ 0.05) difference between treated cells and control. **Statistically significant (P ≤ 0.01)
difference between treated cells and control
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We have previously reported that daphnane diterpenes
can downregulate Mitf [34]. Here, it is most likely that
gnidilatidin-induced inhibition of Mitf (Fig. 5d) was
caused by the downregulation of Id2, causing a decrease
in Rab27a and melanogenic enzymes’ genes Tyr, Tyrp1,
and Dct (Fig. 5e) expression, and this effect was further
validated by the inhibition of melanin content of the
cells presented in Fig. 5g. Enhanced RAB27A expression
has been reported to promote not only melanosome
transport, for effective pigmentation, but also invasive-
ness and metastasis in breast cancer cells [35] (Fig. 5f ).
Rab27a has also been shown to be involved in exocytosis
of insulin and chromaffin granules in endocrine cells.
Autocrine and paracrine cytokines are essential for
invasion and metastasis in some solid tumors and that its
inhibition may also be another effective strategy to prevent
tumor metastasis. Moreover, as overexpression of Rab27a
protein is relevant in the redistribution of the cell cycle,
daphnane diterpenes -rich TH- and gnidilatidin-induced
downregulation of Rab27, therefore, lowers the cancer
cells invasiveness and metastatic abilities.
MITF indirectly regulates CD44 and MMP2 through
the MET proto-oncogene by binding and activating the
MET promoter [36]. Reduction of MITF activity sensi-
tizes melanoma cells to chemotherapeutic agents and
targeting MITF has been suggested to be a rational
therapeutic avenue into highly chemotherapy-resistant
melanoma [15]. Whether the decreased level of CD44
and MMP9 following daphnane diterpenes-rich TH or
gnidilatidin treatment (Fig. 2a and b) was a result of Mitf
inhibition was not determined but is most likely.
Since TH and its daphnane diterpenes components
have antimelanogenesis effect [13, 14], it is not surpris-
ing that gnidilatidin has the same effect (Fig. 5e). The
presence of other daphnane diterpenoids in TH at the
right concentration, and possibly in synergy with each
other, gave it its beneficial effects against metastasis and
melanoma. It will be interesting to find out the effect of
TH on the inflammatory system in vivo, as well as its
effect on other types of cancer. Clinical trials using TH
would be interesting and would enable us to explore its
possible cancer-preventive effects.
Conclusions
Our results demonstrated for the first time that treat-
ment with daphnane diterpenes can significantly inhibit
lung metastasis of B16F10 cells, as demonstrated by the
inhibition of B16F10 cells migration, invasion, and adhe-
sion, associated with suppression of CD44 and MMPs
(MMP2 and MMP9) expression. Moreover, treatment
with gnidilatidin has shown that at the signal transduc-
tion level, gnidilatidin increased the expression of MITF
and the direct regulator of tumor suppressors, Egr1,
accompanied by a downregulation of tumor cell migration
and invasion-associated gene Id2, providing further proof
on the potential of daphnane diterpenes for use as thera-
peutics against melanoma metastasis, either alone or in
combination with other daphnane diterpenes or existing
anti-cancer drugs.
Additional files
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Additional file 2: Figure S1: The protein bands intensity of MMP2 and
MMP9 obtained using Li-COR Software. (PPT 191 kb)
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